Market Cap 10.87M
Revenue (ttm) 0.00
Net Income (ttm) -14.50M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 44,017
Avg Vol 104,094
Day's Range N/A - N/A
Shares Out 3.98M
Stochastic %K 22%
Beta 2.04
Analysts Strong Sell
Price Target $19.20

Company Profile

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non...

Industry: Biotechnology
Sector: Healthcare
Phone: 609 896 9100
Website: imunon.com
Address:
997 Lenox Drive, Suite 100, Lawrenceville, United States
jjegglie
jjegglie May. 13 at 8:04 PM
$IMNN Yet another newb who hasn't performed a single shred of due diligence on celsion. This is a dilution scam. Celsion doesn't give a single shit about cancer. The company exists to keep management paid at the expense of dupes buying the continuous dilution cycles and sick people's health. Every single drug company on the planet has had nearly 2 years to review the p2 data (which, by the way, is fatally flawed and statistically insignificant) and passed on buying the company, which is a rounding error for any legitimate drug company. Also, they dont have a cash runway of $4.7 million. They had a cash runway of $4.7 million. Its currently halfway through the next quarter. The cash balance is half that at best and they will dilute any day now.
0 · Reply
TheManUpstairs
TheManUpstairs May. 13 at 7:48 PM
Let’s be realistic about $IMNN : looking at their current cash runway of just $4.8M against their quarterly burn rate, the company doesn't even have the capital to fund the enrollment of the first 80 patients. But that’s completely missing the point here. Imunon was never meant to finish the OVATION 3 trial independently The strategy here is clear: 1) Secure near-term bridge financing to keep the lights on and stabilize the stock 2) Leverage the FDA-approved protocol to sign a major strategic partnership or buy-out. This is a M&A play. ( ˘▽˘)っ♨
1 · Reply
bomber1
bomber1 May. 13 at 7:17 PM
$IMNN it goes down because they didn't say anything new today; indeed biblical times; very long; they talk about an enrollment of 80 patients by the end of 2027!! but do you realize? 80 patients? but we're joking; on a global phase 3 trial of an oncology product, in a year and a half they still have only 80 patients? will never be able to reach the goal
1 · Reply
LKDOG
LKDOG May. 13 at 6:31 PM
$IMNN 6% drop ? Does not make sense . Will see how it goes 🤷🏻‍♂️
0 · Reply
bxp2390
bxp2390 May. 13 at 1:56 PM
$IMNN I hate to ask you all to do a valuation exercise, but try this "prompt"(even if you choose to do that on your favorite AI). Prompt to any AI: "If a biotech in Phase 3 trials gets approved in 4 years for first-line treatment in ovarian cancer, what could be the market capitalization on approval given the market for ovarian cancer in the US? Then, assume a 25% chance of the FDA approving the drug (much less than the general P3 approval percentage), and discount the valuation to today. What could the company be worth today?" Obviously the bears are going to say that approval probability is zero and modify the prompt for that and we know what the output will be too. But this is the uncertainty here that we all are taking different sides on.
2 · Reply
jjegglie
jjegglie May. 12 at 6:19 PM
$IMNN Straight from the press release. Enrollment won't be completed for another 3 years🤣🤣. I told this board that the trial wouldn't go one day less than the full 7 years, but all the bots, penny stock pooper scoopers and paid pushers merely blocked me for it. Celsion doesn't give a single shit about cancer. This trial is simply a way for management to continue selling worthless shares and maintain their exorbitant salaries. Hopefully, this revelation today will actually save some longs from losing all their money.
0 · Reply
ConcernedCitizen23
ConcernedCitizen23 May. 12 at 5:33 PM
$IMNN the ceo kept talking about doing a fund raise with preferred stock so that the common shareholders don’t get diluted. Sounds great but honestly a buyout is really the right way to go here for everybody
2 · Reply
EarningsInsider
EarningsInsider May. 12 at 4:02 PM
https://www.marketbeat.com/earnings/reports/2026-5-12-imunon-inc-stock/ $IMNN Imunon Earnings Transcript
0 · Reply
Ferryf
Ferryf May. 12 at 1:12 PM
$IMNN IMNN-001 is the First and Only frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enrollment in the Phase 3 OVATION 3 Study of IMNN-001 is expected to be completed by Q1 2029, supported by remarkable Phase 2 data showing significant overall survival improvement FDA has reviewed and is aligned with Phase 3 protocol, confirms path to BLA Filing
0 · Reply
jjegglie
jjegglie May. 12 at 12:47 PM
$IMNN Celsion cqsh burn predictably going up. Bankrupt within 90 days without further dilution. Another massive dilution event any day now
0 · Reply
Latest News on IMNN
Imunon reports Q1 EPS (84c), consensus ($1.28)

2026-05-12T16:03:21.000Z - 1 day ago

Imunon reports Q1 EPS (84c), consensus ($1.28)


Imunon Earnings Call Transcript: Q1 2026

May 12, 2026, 11:00 AM EDT - 1 day ago

Imunon Earnings Call Transcript: Q1 2026


Imunon initiated with a Buy at Maxim

2026-04-17T12:46:27.000Z - 26 days ago

Imunon initiated with a Buy at Maxim


Imunon Earnings Call Transcript: Q4 2025

Mar 31, 2026, 11:00 AM EDT - 6 weeks ago

Imunon Earnings Call Transcript: Q4 2025


Imunon Earnings Call Transcript: Q3 2025

Nov 13, 2025, 11:00 AM EST - 6 months ago

Imunon Earnings Call Transcript: Q3 2025


Imunon reports Q3 EPS ($1.16) vs ($3.76) last year

2025-11-13T12:50:55.000Z - 6 months ago

Imunon reports Q3 EPS ($1.16) vs ($3.76) last year


Imunon expects cash to fund operations into Q1 of 2026

2025-11-13T12:50:47.000Z - 6 months ago

Imunon expects cash to fund operations into Q1 of 2026


Imunon showcases progress on IMNN-001 at R&D Day

2025-11-10T13:00:28.000Z - 6 months ago

Imunon showcases progress on IMNN-001 at R&D Day


Imunon to present Phase 3 OVATION 3 study of IMNN-001

2025-10-30T12:21:17.000Z - 6 months ago

Imunon to present Phase 3 OVATION 3 study of IMNN-001


Imunon to present Phase 3 OVATION trial of IMNN-001

2025-10-14T12:36:43.000Z - 7 months ago

Imunon to present Phase 3 OVATION trial of IMNN-001


Imunon Earnings Call Transcript: Q2 2025

Aug 5, 2025, 11:00 AM EDT - 10 months ago

Imunon Earnings Call Transcript: Q2 2025


Imunon sees cash runway into 4Q25

2025-08-05T12:16:44.000Z - 10 months ago

Imunon sees cash runway into 4Q25


Imunon reports Q2 EPS ($2.15), consensus ($4.99)

2025-08-05T12:10:16.000Z - 10 months ago

Imunon reports Q2 EPS ($2.15), consensus ($4.99)


Imunon board approves 15% stock dividend

2025-07-28T12:20:54.000Z - 10 months ago

Imunon board approves 15% stock dividend


IMUNON Announces Stock Dividend Boosting Shareholder Value

Jul 28, 2025, 8:05 AM EDT - 10 months ago

IMUNON Announces Stock Dividend Boosting Shareholder Value


Imunon announces 1-for-15 reverse split ratio

2025-07-23T12:15:59.000Z - 10 months ago

Imunon announces 1-for-15 reverse split ratio


IMUNON Announces Reverse Stock Split

Jul 23, 2025, 8:00 AM EDT - 10 months ago

IMUNON Announces Reverse Stock Split


Imunon Transcript: Life Sciences Investor Forum

Jun 12, 2025, 11:30 AM EDT - 11 months ago

Imunon Transcript: Life Sciences Investor Forum


Imunon Earnings Call Transcript: Q1 2025

May 12, 2025, 11:00 AM EDT - 1 year ago

Imunon Earnings Call Transcript: Q1 2025


Imunon Earnings Call Transcript: Q4 2024

Feb 27, 2025, 11:00 AM EST - 1 year ago

Imunon Earnings Call Transcript: Q4 2024


IMUNON Appoints Douglas V. Faller, M.D.

Feb 10, 2025, 8:05 AM EST - 1 year ago

IMUNON Appoints Douglas V. Faller, M.D.


jjegglie
jjegglie May. 13 at 8:04 PM
$IMNN Yet another newb who hasn't performed a single shred of due diligence on celsion. This is a dilution scam. Celsion doesn't give a single shit about cancer. The company exists to keep management paid at the expense of dupes buying the continuous dilution cycles and sick people's health. Every single drug company on the planet has had nearly 2 years to review the p2 data (which, by the way, is fatally flawed and statistically insignificant) and passed on buying the company, which is a rounding error for any legitimate drug company. Also, they dont have a cash runway of $4.7 million. They had a cash runway of $4.7 million. Its currently halfway through the next quarter. The cash balance is half that at best and they will dilute any day now.
0 · Reply
TheManUpstairs
TheManUpstairs May. 13 at 7:48 PM
Let’s be realistic about $IMNN : looking at their current cash runway of just $4.8M against their quarterly burn rate, the company doesn't even have the capital to fund the enrollment of the first 80 patients. But that’s completely missing the point here. Imunon was never meant to finish the OVATION 3 trial independently The strategy here is clear: 1) Secure near-term bridge financing to keep the lights on and stabilize the stock 2) Leverage the FDA-approved protocol to sign a major strategic partnership or buy-out. This is a M&A play. ( ˘▽˘)っ♨
1 · Reply
bomber1
bomber1 May. 13 at 7:17 PM
$IMNN it goes down because they didn't say anything new today; indeed biblical times; very long; they talk about an enrollment of 80 patients by the end of 2027!! but do you realize? 80 patients? but we're joking; on a global phase 3 trial of an oncology product, in a year and a half they still have only 80 patients? will never be able to reach the goal
1 · Reply
LKDOG
LKDOG May. 13 at 6:31 PM
$IMNN 6% drop ? Does not make sense . Will see how it goes 🤷🏻‍♂️
0 · Reply
bxp2390
bxp2390 May. 13 at 1:56 PM
$IMNN I hate to ask you all to do a valuation exercise, but try this "prompt"(even if you choose to do that on your favorite AI). Prompt to any AI: "If a biotech in Phase 3 trials gets approved in 4 years for first-line treatment in ovarian cancer, what could be the market capitalization on approval given the market for ovarian cancer in the US? Then, assume a 25% chance of the FDA approving the drug (much less than the general P3 approval percentage), and discount the valuation to today. What could the company be worth today?" Obviously the bears are going to say that approval probability is zero and modify the prompt for that and we know what the output will be too. But this is the uncertainty here that we all are taking different sides on.
2 · Reply
jjegglie
jjegglie May. 12 at 6:19 PM
$IMNN Straight from the press release. Enrollment won't be completed for another 3 years🤣🤣. I told this board that the trial wouldn't go one day less than the full 7 years, but all the bots, penny stock pooper scoopers and paid pushers merely blocked me for it. Celsion doesn't give a single shit about cancer. This trial is simply a way for management to continue selling worthless shares and maintain their exorbitant salaries. Hopefully, this revelation today will actually save some longs from losing all their money.
0 · Reply
ConcernedCitizen23
ConcernedCitizen23 May. 12 at 5:33 PM
$IMNN the ceo kept talking about doing a fund raise with preferred stock so that the common shareholders don’t get diluted. Sounds great but honestly a buyout is really the right way to go here for everybody
2 · Reply
EarningsInsider
EarningsInsider May. 12 at 4:02 PM
https://www.marketbeat.com/earnings/reports/2026-5-12-imunon-inc-stock/ $IMNN Imunon Earnings Transcript
0 · Reply
Ferryf
Ferryf May. 12 at 1:12 PM
$IMNN IMNN-001 is the First and Only frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enrollment in the Phase 3 OVATION 3 Study of IMNN-001 is expected to be completed by Q1 2029, supported by remarkable Phase 2 data showing significant overall survival improvement FDA has reviewed and is aligned with Phase 3 protocol, confirms path to BLA Filing
0 · Reply
jjegglie
jjegglie May. 12 at 12:47 PM
$IMNN Celsion cqsh burn predictably going up. Bankrupt within 90 days without further dilution. Another massive dilution event any day now
0 · Reply
justiceforb_85
justiceforb_85 May. 10 at 10:03 PM
$IMNN has the company indicated when the next clinical update is for the phase 3 OVATION trial?
2 · Reply
ConcernedCitizen23
ConcernedCitizen23 May. 9 at 1:47 PM
$IMNN here’s my value calculation for the fully approved cancer drug $2-4 billion for USA, $2-4 billion for worldwide rights. Since we’re in phase 3 and you discount the potential 90% to make it worthwhile for the acquiring company you still get $400-800million or $100-$200/share
2 · Reply
ConcernedCitizen23
ConcernedCitizen23 May. 9 at 1:28 PM
$IMNN what would this company be worth after FDA approval?!? $2-4 BILLION
0 · Reply
LKDOG
LKDOG May. 8 at 8:10 PM
$IMNN $275 is much better than $2.75 🤑 Sarcasm . Best of luck to all. Has been a very long & emotional ride.
0 · Reply
ConcernedCitizen23
ConcernedCitizen23 May. 8 at 7:11 PM
$IMNN I hope people remember that this tiny company has a great vaccine platform $MRNA $NVAX https://investors.imunon.com/news-releases/news-release-details/imunon-announces-placciner-dna-vaccine-technology-abstract
0 · Reply
BB_88_
BB_88_ May. 7 at 10:46 PM
$IMNN wonder if she moves before earnings
1 · Reply
RaKa82
RaKa82 May. 7 at 6:31 PM
1 · Reply
ConcernedCitizen23
ConcernedCitizen23 May. 6 at 10:43 PM
$IMNN it was eerily quiet today. I bought more. See you all after “change in control” event predicted by the 8-k filing
0 · Reply
ConcernedCitizen23
ConcernedCitizen23 May. 5 at 10:49 PM
$IMNN somebody is planning for a “change in control” of this company. 8K filing
0 · Reply
ConcernedCitizen23
ConcernedCitizen23 May. 5 at 8:47 PM
$IMNN latest sec filing looks like a golden parachute for the ceo and whole team…could be getting ready for something here
1 · Reply
bomber1
bomber1 May. 4 at 8:00 AM
$IMNN it is an old statement dating back to the beginning of April; there is, therefore, nothing new on the horizon; Doctor Thaker is a doctor in the oncology field and a researcher, but is directly involved with the IMN001 trial; he is not an independent doctor and outside of experimentation; it is therefore directly involved; There must be declarations from subjects external and independent of the trial, to have an effect on the title; therefore, as many have written, you are not very prepared, and you post useless titles!!!
0 · Reply
ConcernedCitizen23
ConcernedCitizen23 May. 2 at 12:37 PM
$IMNN nice results explained by a cancer doc https://www.targetedonc.com/view/dr-thaker-highlights-survival-benefit-with-imnn-001-in-ovarian-cancer
0 · Reply